Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

The global market for antithrombotic/anticoagulant drugs should reach $27.3 billion by 2021 from $18.9 billion in 2016 at a compound annual growth rate (CAGR) of 7.6%, from 2016 to 2021.

This report provides:
An overview of the global market for antithrombotic/anticoagulant drugs, which is changing due to factors such as an aging population, an increase in thrombotic events, and recent advances in pharmaceuticals
Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021
Breakdowns of the market size of anticoagulants by revenue at manufacturers' sales levels, including low molecular weight heparins and oral anticoagulants, as well as breakdowns of antiplatelets and thrombin inhibitors
Discussion of research and development of antithrombotic/anticoagulant treatments
Profiles of top leaders in each of the market segments along with companies that are novel or have specific interest to the field


SCOPE OF THE STUDY

This report is a comprehensive business tool designed to provide an in-depth look at antithrombotic/anticoagulant drugs for various cardiovascular applications. The geographic scope of the report is global, with a special emphasis on individual regions such as the United States, Europe, Asia-Pacific and the rest of world. The report describes the industry, its relationship to the healthcare industry and its participants and future trends.

Categories discussed in the report include:
Anticoagulants.
Antiplatelets.
Thrombin inhibitors.

All categories are discussed in detail, describing each segment, identifying current products on the market, measuring market size, identifying market drivers, forecasting for 2016 to 2021 and assessing the competitors their market shares.

CHAPTER 1 Introduction
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THIS STUDY
SCOPE OF THE STUDY
METHODOLOGY AND INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 EXECUTIVE SUMMARY
EXECUTIVE SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015-2021 ($ MILLIONS)
CHAPTER 3 INDUSTRY OVERVIEW
MAJOR DEVELOPMENTS
COAGULATION FACTORS TARGETED TO REDUCE CVD
DEVELOPMENT OF ANTIDOTES FOR THROMBIN INHIBITORS
Andexanet Alfa
Praxbind (Idarucizumab)
TABLE 1 PRAXBIND (IDARUCIZUMAB) DRUG LABEL
SALES PERFORMANCE OF MAJOR DRUGS PROJECTED THROUGH 2020
XARELTO (RIVAROXABAN)
ELIQUIS (APIXABAN)
PRADAXA (DABIGATRAN ETEXILATE MESYLATE)
LOVENOX (ENOXAPARIN)
PLAVIX (CLOPIDOGREL)
TABLE 2 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT
DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
PATENT ANALYSIS
PATENT BY ASSIGNEE
FIGURE 1 COMPANY SHARES OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, JAN. 2011 TO APRIL 2016 (%)
FIGURE 2 COMPANY SHARES OF PATENTS ON ANTICOAGULANTS, JAN. 2011 TO APRIL 2016 (%)
EPIDEMIC OF CARDIOVASCULAR DISEASE
TABLE 3 EPIDEMIC OF CARDIOVASCULAR DISEASES
RISK FACTORS AND PREVENTION OF CVD
CLASSIFICATION OF CARDIOVASCULAR DISEASES
CORONARY HEART DISEASE
Prevalence of CHD in the U.S.
TABLE 4 CORONARY HEART DISEASE PROFILE
TABLE 5 DISTRIBUTION OF HEART DISEASE BY RACE/ETHNICITY, 2013 (%)
ACUTE MYOCARDIAL INFARCTION
TABLE 6 ACUTE MYOCARDIAL INFARCTION DISEASE PROFILE
THE CIRCULATORY SYSTEM
BLOOD VESSEL STRUCTURE
BLOOD FLOW
CONDITIONS
THROMBUS
EMBOLUS
ALTERATIONS IN VENOUS FLOW
DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
TABLE 7 VIRCHOW'S TRIAD: THREE MAIN FACTORS IN PREDISPOSITION
TO PULMONARY EMBOLISM
HEMOSTASIS (THE CLOTTING PROCESS)
DISEASES ASSOCIATED WITH THROMBOEMBOLISM
ACUTE CORONARY SYNDROME
ISCHEMIC HEART DISEASE
Etiology
Mechanisms of Coronary Atherosclerosis
Pathophysiology of Ischemia
ANGINA PECTORIS
CHRONIC ISCHEMIC CARDIOMYOPATHY
SUDDEN CARDIAC DEATH
ATRIAL FIBRILLATION
Causes
CEREBROVASCULAR DISEASE
STENT THROMBOSIS
DEMOGRAPHICS
TABLE 8 GLOBAL POPULATION BY SELECTED REGION, 2000-2050 (MILLIONS)
TABLE 9 GLOBAL POPULATION GROWTH BY SELECTED REGION, 2000-2050 (AVERAGE PERCENTAGE GROWTH PER YEAR)
FIGURE 3 GLOBAL POPULATION GROWTH BY SELECTED REGION, 2000-2050 (AVERAGE PERCENTAGE GROWTH)
CV, VTE, AF AND STROKE DEMOGRAPHICS
Venous Thromboembolism
Venous Thromboembolism and Lifestyle
Venous Thromboembolism and Air Travel
CHAPTER 4 ANTICOAGULANTS
OVERVIEW
PRODUCTS
LOW MOLECULAR WEIGHT HEPARIN
Lovenox
TABLE 10 LOVENOX DRUG LABEL
Fragmin
TABLE 11 FRAGMIN DRUG LABEL
Innohep
TABLE 12 INNOHEP DRUG LABEL
Orgaran
TABLE 13 ORGARAN DRUG LABEL
Normiflo
TABLE 14 NORMIFLO DRUG LABEL
Embolex
TABLE 15 EMBOLEX DRUG LABEL
Fraxiparine
TABLE 16 FRAXIPARINE DRUG LABEL
Ariven/Arteven
TABLE 17 ARIVEN/ARTEVEN DRUG LABEL
ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS)
GLOBAL MARKET FORECAST
TABLE 18 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY REGION, 2015-2021 ($ MILLIONS)
MARKET BY GEOGRAPHIC REGION
TABLE 19 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 (%)
FIGURE 5 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2015 (%)
TABLE 20 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 (%)
FIGURE 6 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY REGION, 2021 (%)
MARKET BY DRUG TYPE
TABLE 21 GLOBAL MARKET FOR ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 ($ MILLIONS)
TABLE 22 GLOBAL MARKET FOR LOW MOLECULAR WEIGHT HEPARIN BY REGION, THROUGH 2021 ($ MILLIONS)
TABLE 23 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 7 GLOBAL MARKET FOR ORAL ANTICOAGULANTS (VITAMIN K ANTAGONISTS) BY REGION, 2015-2021 ($ MILLIONS)
TABLE 24 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2015 (%)
FIGURE 8 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2015 (%)
TABLE 25 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2021 (%)
FIGURE 9 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY TYPE, 2021 (%)
COMPETITIVE ANALYSIS
TABLE 26 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%)
FIGURE 10 GLOBAL MARKET SHARES OF ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)
CHAPTER 5 ANTIPLATELETS
OVERVIEW
PRODUCTS
ORAL ANTIPLATELETS
Plavix
TABLE 27 PLAVIX DRUG LABEL
Pletal
TABLE 28 PLETAL DRUG LABEL
Effient
TABLE 29 EFFIENT DRUG LABEL
Ticlid
Brilinta
TABLE 30 BRILINTA DRUG LABEL
IV ANTIPLATELETS
Integrilin
TABLE 31 INTEGRILIN DRUG LABEL
Aggrastat
TABLE 32 AGGRASTAT DRUG LABEL
ReoPro
TABLE 33 REOPRO DRUG LABEL
GLOBAL MARKET FORECAST
TABLE 34 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 11 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY REGION, 2015-2021 ($ MILLIONS)
MARKET BY GEOGRAPHIC REGION
TABLE 35 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2015 (%)
FIGURE 12 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2015 (%)
TABLE 36 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2021 (%)
FIGURE 13 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY REGION, 2021 (%)
MARKET BY DRUG TYPE
TABLE 37 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, THROUGH 2021 ($ MILLIONS)
FIGURE 14 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY TYPE, 2015-2021 ($ MILLIONS)
TABLE 38 GLOBAL MARKET FOR ORAL ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
TABLE 39 GLOBAL MARKET FOR IV ANTIPLATELET DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
TABLE 40 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2015 (%)
FIGURE 15 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2015 (%)
TABLE 41 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2021 (%)
FIGURE 16 GLOBAL MARKET SHARES OF ANTIPLATELET DRUGS BY TYPE, 2021 (%)
COMPETITIVE ANALYSIS
TABLE 42 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%)
FIGURE 17 GLOBAL MARKET FOR ANTIPLATELET DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)
CHAPTER 6 THROMBIN INHIBITORS
OVERVIEW
PRODUCTS
DIRECT THROMBIN INHIBITORS
Argatroban
Angiomax
Iprivask
Pradaxa
THROMBOLYTIC AGENTS
Thrombolytic Enzymes
Tissue Plasminogen Activators
Activase
Retavase
TNKase
ATryn
DIRECT FACTOR XA INHIBITORS
Xarelto
Betrixaban
Savaysa (Edoxaban)
Eliquis
GLOBAL THROMBIN INHIBITOR MARKET FORECAST
TABLE 43 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 18 GLOBAL MARKET FOR THROMBIN INHIBITORS BY REGION, 2015-2021 ($ MILLIONS)
REGIONAL MARKET SHARES OF THROMBIN INHIBITORS
TABLE 44 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 (%)
FIGURE 19 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2015 (%)
TABLE 45 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 (%)
FIGURE 20 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY REGION, 2021 (%)
MARKET BY DRUG TYPE
TABLE 46 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, THROUGH 2021 ($ MILLIONS)
FIGURE 21 GLOBAL MARKET FOR THROMBIN INHIBITORS BY TYPE, 2015-2021 ($ MILLIONS)
TABLE 47 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, 2015 (%)
FIGURE 22 GLOBAL MARKET SHARES OF THROMBIN INHIBITORS BY TYPE, 2015 (%)
TABLE 48 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 (%)
FIGURE 23 GLOBAL MARKET SHARES OF SALES OF THROMBIN INHIBITORS BY TYPE, 2021 (%)
TABLE 49 GLOBAL MARKET FOR THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 ($ MILLIONS/%)
FIGURE 24 GLOBAL MARKET SHARES OF THROMBIN INHIBITOR DRUGS BY COMPANY, 2014 (%)
RESEARCH AND DEVELOPMENT
GLOBAL ANTICOAGULANT/ANTITHROMBOTIC MARKET FORECAST
TABLE 50 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, THROUGH 2021 ($ MILLIONS)
FIGURE 25 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2015-2021 ($ MILLIONS)
TABLE 51 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2015 (%)
FIGURE 26 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2015 (%)
TABLE 52 GLOBAL MARKET SHARES OF ANTITHROMBIN/ANTICOAGULANT DRUGS BY TYPE, 2021 (%)
FIGURE 27 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY TYPE, 2021 (%)
MARKET BY GEOGRAPHIC REGION
TABLE 53 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 28 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015-2021 ($ MILLIONS)
TABLE 54 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 (%)
FIGURE 29 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2015 (%)
TABLE 55 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 (%)
FIGURE 30 GLOBAL MARKET SHARES OF ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY REGION, 2021 (%)
COMPETITIVE ANALYSIS
TABLE 56 GLOBAL MARKET FOR ANTITHROMBIN/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 ($ MILLIONS/%)
FIGURE 31 GLOBAL MARKET FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS BY COMPANY, COMPETITIVE ANALYSIS, 2014 (%)
CHAPTER 7 COMPANY PROFILES
ABBOTT LABORATORIES
HISTORY
RECENT DEVELOPMENTS
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
ARMETHEON INC.
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
CORPORATE MANAGEMENT
ASTRAZENECA
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATIONS
CORPORATE MANAGEMENT
BAXTER INTERNATIONAL
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATIONS
CORPORATE MANAGEMENT
BAYER AG
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATIONS
CORPORATE MANAGEMENT
BIOVASCULAR INC.
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
BOEHRINGER INGELHEIM GMBH
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATIONS
CORPORATE MANAGEMENT
BRISTOL-MYERS SQUIBB CO.
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATIONS
CORPORATE MANAGEMENT
CSL BEHRING
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATIONS
CORPORATE MANAGEMENT
DAIICHI SANKYO CO. LTD.
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATIONS
CORPORATE MANAGEMENT
ELI LILLY
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
EMISPHERE TECHNOLOGIES
HISTORY
PRODUCTS
CORPORATE MANAGEMENT
F. HOFFMANN-LA ROCHE AG
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATIONS
CORPORATE MANAGEMENT
GENENTECH
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
GLAXOSMITHKLINE
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
JOHNSON & JOHNSON
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATIONS
CORPORATE MANAGEMENT
LIGAND PHARMACEUTICALS INC.
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
THE MEDICINES CO.
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
CORPORATE MANAGEMENT
MERCK
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
MERRION PHARMACEUTICALS LTD.
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
MICROBIX BIOSYSTEMS INC.
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
NOVARTIS
HISTORY
PRODUCTS
RECENT DEVELOPMENTS:
LOCATIONS
CORPORATE MANAGEMENT
ONO PHARMACEUTICAL CO. LTD.
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
OTSUKA PHARMACEUTICAL CO. LTD.
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATIONS
CORPORATE MANAGEMENT
PFIZER INC.
HISTORY
PRODUCTS
RECENT DEVELOPMENTS:
CORPORATE MANAGEMENT
PORTOLA PHARMACEUTICALS
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATION
CORPORATE MANAGEMENT
REVO BIOLOGICS INC.
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
SANOFI
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
SANTA CRUZ BIOTECHNOLOGY INC.
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
SERVIER LABORATORIES
HISTORY
LOCATIONS
CORPORATE MANAGEMENT
SHIRE PHARMACEUTICALS
HISTORY
PRODUCTS
LOCATIONS
CORPORATE MANAGEMENT
SUN PHARMACEUTICALS
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATIONS
CORPORATE MANAGEMENT
TEVA PHARMACEUTICALS LTD.
HISTORY
PRODUCTS
RECENT DEVELOPMENTS
LOCATIONS
CORPORATE MANAGEMENT
CHAPTER 8 APPENDIX A: LIST OF PATENTS
TABLE 57 LIST OF PATENTS ON ANTITHROMBOTICS AND ANTICOAGULANTS, 2011-APRIL 2016
CHAPTER 9 APPENDIX B: DIRECTORY OF COMPANIES COVERED IN THIS REPORT

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook